Inhibition of microRNA‑492 attenuates cell proliferation and invasion in retinoblastoma via directly targeting LATS2

Sun,Zhiqun; Zhang,Aimei; Zhang,Liming

doi:10.3892/mmr.2018.9784

Inhibition of microRNA‑492 attenuates cell proliferation and invasion in retinoblastoma via directly targeting LATS2

Authors:
- Zhiqun Sun
- Aimei Zhang
- Liming Zhang
View Affiliations

Affiliations: Department of Pediatrics, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China
Published online on: December 20, 2018 https://doi.org/10.3892/mmr.2018.9784
Pages: 1965-1971

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous studies have demonstrated that microRNAs (miRNAs) are upregulated or downregulated in retinoblastoma (RB), and that this phenomenon is associated with the modulation of various malignant behaviours during RB occurrence and development. Therefore, the mechanisms that associate deregulated miRNAs with RB initiation and progression must be understood to identify effective therapeutic techniques for patients with RB. In the present study, miR‑492 expression was upregulated in RB tissues and cell lines. The effects of miR‑492 inhibition on the proliferation and invasion of RB cells were examined using Cell Counting kit‑8 and invasion assays. The results revealed that miR‑492 downregulation significantly decreased the proliferation and invasion of RB cells. Bioinformatics analysis predicted that large tumour‑suppressor kinase 2 (LATS2) was a putative target of miR‑492. Luciferase reporter assay, reverse transcription‑quantitative polymerase chain reaction and western blot analysis demonstrated that LATS2 was a direct target gene of miR‑492 in RB cells. In addition, LATS2 expression was downregulated in RB tissues, and its downregulation was inversely correlated with miR‑492 level. Furthermore, LATS2‑knockdown abrogated the effects of miR‑492 downregulation in RB cells. In conclusion, miR‑492 inhibition may impede the malignant behaviour of RB by directly targeting LATS2. Therefore, targeting this miRNA may be an effective therapeutic method for treating patients with RB.

View Figures

View References

1	Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, Abramson DH, Shields CL, Chantada GL, Njuguna F and Gallie BL: Retinoblastoma. Nat Rev Dis Primers. 1:150212015. View Article : Google Scholar : PubMed/NCBI
2	Broaddus E, Topham A and Singh AD: Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol. 93:21–23. 2009. View Article : Google Scholar : PubMed/NCBI
3	MacCarthy A, Draper GJ, Steliarova-Foucher E and Kingston JE: Retinoblastoma incidence and survival in European children (1978–1997). Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 42:2092–2102. 2006. View Article : Google Scholar : PubMed/NCBI
4	Benavente CA and Dyer MA: Genetics and epigenetics of human retinoblastoma. Annu Rev Pathol. 10:547–562. 2015. View Article : Google Scholar : PubMed/NCBI
5	Shields CL and Shields JA: Retinoblastoma management: Advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 21:203–212. 2010. View Article : Google Scholar : PubMed/NCBI
6	Dimaras H, Dimba EA and Gallie BL: Challenging the global retinoblastoma survival disparity through a collaborative research effort. Br J Ophthalmol. 94:1415–1416. 2010. View Article : Google Scholar : PubMed/NCBI
7	Wu X, Zeng Y, Wu S, Zhong J, Wang Y and Xu J: MiR-204, down-regulated in retinoblastoma, regulates proliferation and invasion of human retinoblastoma cells by targeting CyclinD2 and MMP-9. FEBS Lett. 589:645–650. 2015. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Cai Y, Yu X, Hu S and Yu J: A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
10	Pratap P, Raza ST, Abbas S and Mahdi F: MicroRNA-associated carcinogenesis in lung carcinoma. J Cancer Res Ther. 14:249–254. 2018.PubMed/NCBI
11	Vannini I, Fanini F and Fabbri M: Emerging roles of microRNAs in cancer. Curr Opin Genet Dev. 48:128–133. 2018. View Article : Google Scholar : PubMed/NCBI
12	Lou W, Liu J, Gao Y, Zhong G, Chen D, Shen J, Bao C, Xu L, Pan J, Cheng J, et al: MicroRNAs in cancer metastasis and angiogenesis. Oncotarget. 8:115787–115802. 2017. View Article : Google Scholar : PubMed/NCBI
13	Liu S, Zhang X, Hu C, Wang Y and Xu C: miR-29a inhibits human retinoblastoma progression by targeting STAT3. Oncol Rep. 39:739–746. 2018.PubMed/NCBI
14	Wang Z, Yao YJ, Zheng F, Guan Z, Zhang L, Dong N and Qin WJ: Mir-138-5p acts as a tumor suppressor by targeting pyruvate dehydrogenase kinase 1 in human retinoblastoma. Eur Rev Med Pharmacol Sci. 21:5624–5629. 2017.PubMed/NCBI
15	Yang L, Wei N, Wang L, Wang X and Liu QH: miR-498 promotes cell proliferation and inhibits cell apoptosis in retinoblastoma by directly targeting CCPG1. Childs Nerv Syst. 34:417–422. 2018. View Article : Google Scholar : PubMed/NCBI
16	Zhang M, Li Q, Pan Y, Wang H, Liu G and Yin H: MicroRNA-655 attenuates the malignant biological behaviours of retinoblastoma cells by directly targeting PAX6 and suppressing the ERK and p38 MAPK signalling pathways. Oncol Rep. 39:2040–2050. 2018.PubMed/NCBI
17	Singh U, Malik MA, Goswami S, Shukla S and Kaur J: Epigenetic regulation of human retinoblastoma. Tumour Biol. 37:14427–14441. 2016. View Article : Google Scholar : PubMed/NCBI
18	Golabchi K, Soleimani-Jelodar R, Aghadoost N, Momeni F, Moridikia A, Nahand JS, Masoudifar A, Razmjoo H and Mirzaei H: MicroRNAs in retinoblastoma: Potential diagnostic and therapeutic biomarkers. J Cell Physiol. 233:3016–3023. 2018. View Article : Google Scholar : PubMed/NCBI
19	Xu X, Ge S, Jia R, Zhou Y, Song X, Zhang H and Fan X: Hypoxia-induced miR-181b enhances angiogenesis of retinoblastoma cells by targeting PDCD10 and GATA6. Oncol Rep. 33:2789–2796. 2015. View Article : Google Scholar : PubMed/NCBI
20	Liu M, An J, Huang M, Wang L, Tu B, Song Y, Ma K, Wang Y, Wang S, Zhu H, et al: MicroRNA-492 overexpression involves in cell proliferation, migration, and radiotherapy response of cervical squamous cell carcinomas. Mol Carcinog. 57:32–43. 2018. View Article : Google Scholar : PubMed/NCBI
21	Song X, Xie Y, Liu Y, Shao M and Yang W: MicroRNA-492 overexpression exerts suppressive effects on the progression of osteosarcoma by targeting PAK7. Int J Mol Med. 40:891–897. 2017. View Article : Google Scholar : PubMed/NCBI
22	Wu A, Wu K, Li M, Bao L, Shen X, Li S, Li J and Yang Z: Upregulation of microRNA-492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro. Mol Med Rep. 12:1413–1420. 2015. View Article : Google Scholar : PubMed/NCBI
23	Jiang J, Zhang Y, Yu C, Li Z, Pan Y and Sun C: MicroRNA-492 expression promotes the progression of hepatic cancer by targeting PTEN. Cancer Cell Int. 14:952014. View Article : Google Scholar : PubMed/NCBI
24	Shen F, Cai WS, Feng Z, Li JL, Chen JW, Cao J and Xu B: MiR-492 contributes to cell proliferation and cell cycle of human breast cancer cells by suppressing SOX7 expression. Tumour Biol. 36:1913–1921. 2015. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	von Frowein J, Hauck SM, Kappler R, Pagel P, Fleischmann KK, Magg T, Cairo S, Roscher A, von Schweinitz D and Schmid I: MiR-492 regulates metastatic properties of hepatoblastoma via CD44. Liver Int. 38:1280–1291. 2018. View Article : Google Scholar : PubMed/NCBI
27	von Frowein J, Pagel P, Kappler R, von Schweinitz D, Roscher A and Schmid I: MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. Hepatology. 53:833–842. 2011. View Article : Google Scholar : PubMed/NCBI
28	Pearce LR, Komander D and Alessi DR: The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 11:9–22. 2010. View Article : Google Scholar : PubMed/NCBI
29	Jimenez-Velasco A, Roman-Gomez J, Agirre X, Barrios M, Navarro G, Vazquez I, Prosper F, Torres A and Heiniger A: Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia. 19:2347–2350. 2005. View Article : Google Scholar : PubMed/NCBI
30	Takahashi Y, Miyoshi Y, Morimoto K, Taguchi T, Tamaki Y and Noguchi S: Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers. J Cancer Res Clin Oncol. 133:501–509. 2007. View Article : Google Scholar : PubMed/NCBI
31	Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, Harada S, Schmidt A, Rodan GA, Freedman LP and Bai C: The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol. 18:2011–2023. 2004. View Article : Google Scholar : PubMed/NCBI
32	Chakraborty S, Khare S, Dorairaj SK, Prabhakaran VC, Prakash DR and Kumar A: Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics. 90:344–353. 2007. View Article : Google Scholar : PubMed/NCBI